| Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group F Mosele, J Remon, J Mateo, CB Westphalen, F Barlesi, MP Lolkema, ... Annals of Oncology 31 (11), 1491-1505, 2020 | 926 | 2020 |
| Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non–small cell lung cancer L Mezquita, E Auclin, R Ferrara, M Charrier, J Remon, D Planchard, ... JAMA oncology 4 (3), 351-357, 2018 | 718 | 2018 |
| Hyperprogressive disease in patients with advanced non–small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy R Ferrara, L Mezquita, M Texier, J Lahmar, C Audigier-Valette, ... JAMA oncology 4 (11), 1543-1552, 2018 | 693 | 2018 |
| First-line immunotherapy for non–small-cell lung cancer M Reck, J Remon, MD Hellmann Journal of Clinical Oncology 40 (6), 586-597, 2022 | 433 | 2022 |
| Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients J Remon, CE Steuer, SS Ramalingam, E Felip Annals of Oncology 29, i20-i27, 2018 | 234 | 2018 |
| Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy J Remon, JC Soria, S Peters Annals of Oncology 32 (12), 1637-1642, 2021 | 188 | 2021 |
| Osimertinib benefit inEGFR-mutant NSCLC patients withT790M-mutation detected by circulating tumour DNA J Remon, C Caramella, C Jovelet, L Lacroix, A Lawson, S Smalley, ... Annals of Oncology 28 (4), 784-790, 2017 | 184 | 2017 |
| Leptomeningeal carcinomatosis in non-small cell lung cancer patients: a continuing challenge in the personalized treatment era J Remon, E Le Rhun, B Besse Cancer treatment reviews 53, 128-137, 2017 | 184 | 2017 |
| Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: a new era begins J Remon, T Moran, M Majem, N Reguart, E Dalmau, D Marquez-Medina, ... Cancer treatment reviews 40 (1), 93-101, 2014 | 148 | 2014 |
| Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers F Facchinetti, Y Loriot, MS Kuo, L Mahjoubi, L Lacroix, D Planchard, ... Clinical Cancer Research 22 (24), 5983-5991, 2016 | 145 | 2016 |
| Immune checkpoint inhibitors in thoracic malignancies: review of the existing evidence by an IASLC expert panel and recommendations J Remon, F Passiglia, MJ Ahn, F Barlesi, PM Forde, EB Garon, ... Journal of Thoracic Oncology 15 (6), 914-947, 2020 | 144 | 2020 |
| Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset H Blons, JF Emile, K Le Malicot, C Julié, A Zaanan, J Tabernero, E Mini, ... Annals of oncology 25 (12), 2378-2385, 2014 | 130 | 2014 |
| EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins J Remon, LEL Hendriks, AF Cardona, B Besse Cancer treatment reviews 90, 102105, 2020 | 128 | 2020 |
| Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and … G Viscardi, AC Tralongo, F Massari, M Lambertini, V Mollica, A Rizzo, ... European Journal of Cancer 177, 175-185, 2022 | 120 | 2022 |
| Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in ALK-Rearranged Non–Small-Cell Lung Cancer E Pailler, V Faugeroux, M Oulhen, L Mezquita, M Laporte, A Honoré, ... Clinical Cancer Research 25 (22), 6671-6682, 2019 | 117 | 2019 |
| LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value F Facchinetti, MV Bluthgen, G Tergemina-Clain, L Faivre, JP Pignon, ... Lung Cancer 112, 62-68, 2017 | 115 | 2017 |
| Common EGFR-Mutated Subgroups (Del19/L858R) in Advanced Non-Small-Cell Lung Cancer: Chasing Better Outcomes with Tyrosine Kinase Inhibitors N Reguart, J Remon Future Oncology 11 (8), 1245-1257, 2015 | 104 | 2015 |
| The APPLE trial: feasibility and activity of AZD9291 (osimertinib) treatment on positive plasma T790M in EGFR-mutant NSCLC patients. EORTC 1613 J Remon, J Menis, B Hasan, A Peric, E De Maio, S Novello, M Reck, ... Clinical lung cancer 18 (5), 583-588, 2017 | 100 | 2017 |
| Circulating T-cell immunosenescence in patients with advanced non–small cell lung cancer treated with single-agent PD-1/PD-L1 inhibitors or platinum-based chemotherapy R Ferrara, M Naigeon, E Auclin, B Duchemann, L Cassard, JM Jouniaux, ... Clinical Cancer Research 27 (2), 492-503, 2021 | 97 | 2021 |
| Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer? J Remon, B Besse, JC Soria BMC medicine 15, 1-7, 2017 | 97 | 2017 |
